Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma (Q36694607)

15 August 2017

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma (English)

1 reference

15 August 2017

12

G Ehninger

1 reference

15 August 2017

R Naumann

1

1 reference

15 August 2017

B Beuthien-Baumann

2

1 reference

15 August 2017

A Reiss

3

1 reference

15 August 2017

J Schulze

4

1 reference

15 August 2017

A Hänel

5

1 reference

15 August 2017

J Bredow

6

1 reference

15 August 2017

G Kühnel

7

1 reference

15 August 2017

J Kropp

8

1 reference

15 August 2017

M Hänel

9

1 reference

15 August 2017

M Laniado

10

1 reference

15 August 2017

J Kotzerke

11

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

90

1 reference

15 August 2017

3

1 reference

15 August 2017

620-625

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601561

15 August 2017

0 references

cites work

PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Positron emission tomography in the management of lymphomas.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Whole body positron emission tomography in the treatment of Hodgkin disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Report of the Committee on Hodgkin's Disease Staging Classification

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

The applications of PET in clinical oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Positron emission tomography for the staging of Hodgkin's lymphoma--increasing the body of evidence in favor of the method

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Can[18F] fluorodeoxyglucose positron emission tomography replace bone marrow biopsy in staging of malignant lymphoma?

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Utility of FDG-PET scanning in lymphoma by WHO classification

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Simultaneous occurrence of Hodgkin's lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409608

The value of laparotomy and splenectomy in the staging of Hodgkin's disease

5 September 2018

1 reference

12 December 2020

Bilateral Trephine Bone Marrow Biopsies in Lymphoma and Other Neoplastic Diseases

1 reference

12 December 2020

Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease

1 reference

12 December 2020

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

12 December 2020

Extranodal malignant lymphoma: detection with FDG PET versus CT

1 reference

12 December 2020

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow

1 reference

12 December 2020

Detection of lymphoma in bone marrow by whole-body positron emission tomography

1 reference

12 December 2020

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

1 reference

12 December 2020

FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601561

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

14760374

1 reference